PF-06252616

( DrugBank: PF-06252616 / KEGG DRUG: Domagrozumab )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
113	筋ジストロフィー	9

113. 筋ジストロフィー

臨床試験数 : 646 / 薬物数 : 471 - (DrugBank : 105) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 170

trials per page:

Showing 1 to 9 of 9 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2016-001615-21-BG (EUCTR)	06/07/2018	12/04/2018	An extension to Protocol B5161002 to evaluate the long-term safety of as well as to collect data reg ...	A Multicenter, Open-Label Extension Study to Evaluate the Long Term Safety of PF-06252616in Boys wit ...	Duchenne's Muscular Dystrophy MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duch ...	Product Code: PF-06252616 INN or Proposed INN: PF-06252616	Pfizer Inc. 235 East 42nd Street, New York, NY 10017	NULL	Not Recruiting			Female: no Male: yes	105	Phase 2	United States;Canada;Poland;Australia;Bulgaria;Japan;Italy;United Kingdom
2	EUCTR2016-001615-21-IT (EUCTR)	06/02/2017	09/01/2017	An extension to Protocol B5161002 to evaluate the long-term safety of as well as to collect data reg ...	A Multicenter, Open-Label Extension Study to Evaluate the Long Term Safety of PF-06252616in Boys wit ...	Duchenne's Muscular Dystrophy MedDRA version: 19.0;Level: PT;Classification code 10013801;Term: Duch ...	Product Code: PF-06252616 INN or Proposed INN: PF-06252616 Product Code: PF-06252616 INN or Proposed IN ...	Pfizer Inc. 235 East 42nd Street, New York, NY 10017	NULL	Not Recruiting			Female: no Male: yes	95	Phase 2	United States;Canada;Poland;Australia;Bulgaria;United Kingdom;Japan;Italy
3	EUCTR2014-002072-92-BG (EUCTR)	29/12/2016	18/10/2016	A Phase 2 Study to Evaluate The Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-062526 ...	A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate Th ...	Duchenne's Muscular Dystrophy MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duch ...	Product Code: PF-06252616 INN or Proposed INN: PF-06252616 Product Code: PF-06252616 INN or Proposed IN ...	Pfizer Inc. 235 East 42nd Street, New York, NY 10017	NULL	Not Recruiting			Female: no Male: yes	105	Phase 2	United States;Canada;Poland;Australia;Bulgaria;Japan;Italy;United Kingdom
4	EUCTR2016-001615-21-GB (EUCTR)	12/12/2016	21/10/2016	An extension to Protocol B5161002 to evaluate the long-term safety of as well as to collect data reg ...	A Multicenter, Open-Label Extension Study to Evaluate the Long Term Safety of PF-06252616in Boys wit ...	Duchenne's Muscular Dystrophy MedDRA version: 19.0;Level: PT;Classification code 10013801;Term: Duch ...	Product Code: PF-06252616 INN or Proposed INN: PF-06252616	Pfizer Inc.	NULL	Not Recruiting			Female: no Male: yes	105	Phase 2	United States;Canada;Poland;Australia;Bulgaria;Japan;Italy;United Kingdom
5	NCT02907619 (ClinicalTrials.gov)	October 13, 2016	14/9/2016	An Open-label Extension Study To Evaluate Safety Of PF-06252616In Boys With Duchenne Muscular Dystro ...	A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY OF PF-06252616IN BOYS WIT ...	Duchenne Muscular Dystrophy	Biological: PF-06252616	Pfizer	NULL	Terminated	6 Years	18 Years	Male	59	Phase 2	United States;Canada;Italy;Japan;United Kingdom
6	EUCTR2014-002072-92-PL (EUCTR)	10/08/2016	14/07/2016	A Phase 2 Study to Evaluate The Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-062526 ...	A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate Th ...	Duchenne's Muscular Dystrophy MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duch ...	Product Code: PF-06252616 INN or Proposed INN: PF-06252616 Product Code: PF-06252616 INN or Proposed IN ...	Pfizer Inc. 235 East 42nd Street, New York, NY 10017	NULL	Not Recruiting			Female: no Male: yes	120	Phase 2	United States;Canada;Poland;Australia;Bulgaria;Japan;Italy;United Kingdom
7	EUCTR2014-002072-92-IT (EUCTR)	05/03/2015	12/01/2015	A Phase 2 Study to Evaluate The Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-062526 ...	A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate Th ...	Duchenne's Muscular Dystrophy MedDRA version: 17.1;Level: PT;Classification code 10013801;Term: Duch ...	Product Code: PF-06252616 INN or Proposed INN: - Other descriptive name: PF-06252616	Pfizer Inc. 235 East 42nd Street, New York, NY 10017	NULL	Not Recruiting			Female: no Male: yes	105	Phase 2	United States;Canada;Poland;Bulgaria;United Kingdom;Japan;Italy
8	EUCTR2014-002072-92-GB (EUCTR)	30/12/2014	16/09/2014	A Phase 2 Study to Evaluate The Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-062526 ...	A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate Th ...	Duchenne's Muscular Dystrophy MedDRA version: 19.0;Level: PT;Classification code 10013801;Term: Duch ...	Product Code: PF-06252616 INN or Proposed INN: PF-06252616 Product Code: PF-06252616 INN or Proposed IN ...	Pfizer Inc. 235 East 42nd Street, New York, NY 10017	NULL	Not Recruiting			Female: no Male: yes	105	Phase 2	United States;Canada;Poland;Australia;Bulgaria;Japan;Italy;United Kingdom
9	NCT02310763 (ClinicalTrials.gov)	November 24, 2014	4/11/2014	A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-062526 ...	A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE ASCENDING DOSE STUDY TO EVALUATE TH ...	Duchenne Muscular Dystrophy	Biological: PF-06252616;Drug: Placebo	Pfizer	NULL	Terminated	6 Years	15 Years	Male	121	Phase 2	United States;Australia;Bulgaria;Canada;Italy;Japan;Poland;United Kingdom

First Previous1Next Last